July 24, 2023 03:04 PM EDTUpdated 03:33 PM

ViiV's long-acting HIV injectable Cabenuva preferred over Biktarvy by 90% of patients in PhIII trial

Katherine Lewin

News Reporter

Most HIV patients in a Phase III study investigating ViiV Healthcare’s long-acting injectable Cabenuva and Gilead Sciences’ daily pill Biktarvy preferred the injection over the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ViiV's long-acting HIV injectable Cabenuva preferred over Biktarvy by 90% of patients in PhIII trial

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Vi­iV's long-act­ing HIV in­jectable Cabe­nu­va pre­ferred over Bik­tarvy by 90% of pa­tients in PhI­II tri­al

News Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

ViiV's long-acting HIV injectable Cabenuva preferred over Biktarvy by 90% of patients in PhIII trial